Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) received a $176.00 price objective from stock analysts at Piper Jaffray Cos. in a report released on Monday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would indicate a potential upside of 46.23% from the company’s current price.

Other research analysts have also issued research reports about the stock. Cowen and Company reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, September 22nd. Citigroup Inc. raised their price objective on shares of Alexion Pharmaceuticals from $154.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, September 20th. Leerink Swann reiterated a “buy” rating and set a $200.00 price objective on shares of Alexion Pharmaceuticals in a research note on Sunday, July 17th. Stifel Nicolaus lowered their price objective on shares of Alexion Pharmaceuticals from $195.00 to $182.00 and set a “buy” rating on the stock in a research note on Friday, July 29th. Finally, Vetr lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price objective on the stock. in a research note on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $173.36.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 120.36 on Monday. The stock has a market cap of $26.98 billion, a price-to-earnings ratio of 73.39 and a beta of 1.45. Alexion Pharmaceuticals has a 52 week low of $110.56 and a 52 week high of $193.45. The firm’s 50 day moving average price is $123.44 and its 200-day moving average price is $130.09.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, beating the Zacks’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business had revenue of $799 million for the quarter, compared to analyst estimates of $787.07 million. During the same quarter last year, the business earned $1.16 earnings per share. The business’s revenue for the quarter was up 19.9% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $4.64 EPS for the current year.

In other news, Director Alvin S. Parven sold 15,000 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the transaction, the director now owns 6,373 shares in the company, valued at approximately $870,105.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Leonard Bell sold 37,317 shares of the firm’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the transaction, the director now owns 440,936 shares in the company, valued at approximately $61,898,595.68. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global X Management Co. LLC increased its position in Alexion Pharmaceuticals by 1,416.4% in the third quarter. Global X Management Co. LLC now owns 925 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 864 shares in the last quarter. Cornerstone Advisors Inc. increased its position in Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 310 shares in the last quarter. NEXT Financial Group Inc increased its position in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Acrospire Investment Management LLC increased its position in Alexion Pharmaceuticals by 50.0% in the third quarter. Acrospire Investment Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 400 shares in the last quarter. Finally, Bellwether Investment Group LLC acquired a new position in Alexion Pharmaceuticals during the second quarter worth $172,000. Institutional investors and hedge funds own 97.33% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.